Is Orlistat as Effective as Mounjaro for Weight Loss?

Step 1, understand what each medicine is actually doing

Orlistat works in the gut. It inhibits pancreatic and gastric lipase, the enzymes that break down dietary fat so your body can absorb it. Block those enzymes and roughly a third of the fat you eat passes through undigested. That is the entire mechanism. It has no effect on appetite, blood sugar, or hormones. The practical consequence (and the one people learn quickly) is that eating a high-fat meal while taking orlistat causes oily, loose stools. The medicine is making the side effects of a fatty diet immediately visible. For some people that feedback loop is motivating; for others it is unworkable.

Mounjaro does something structurally different. Tirzepatide is a dual agonist: it activates both the GIP receptor and the GLP-1 receptor, two pathways involved in appetite signalling, insulin secretion, and how fast food leaves the stomach. The result is that hunger drops, fullness comes sooner, and cravings reduce, changes that happen at a hormonal level rather than in the gut lumen. You can read a detailed breakdown of the mechanism on the tirzepatide overview page.

Understanding this distinction matters because the two medicines suit different situations. Orlistat is effective only if dietary fat is the primary driver of excess calorie intake and the person can consistently follow a low-fat diet. Mounjaro addresses appetite biology more broadly. That is not a value judgement, it is pharmacology.

Step 2, compare the evidence on weight loss

If you have been searching this question, you are probably hoping for a clear number. Here it is. In SURMOUNT-1, a 72-week trial of 2,539 adults with obesity, participants taking tirzepatide 15mg lost an average of around 20–21% of their body weight. Participants on lower doses (5mg and 10mg) lost around 16–19%. These are averages from a blinded, placebo-controlled setting (real-world results vary) but the signal is consistent and reproduced across the full Mounjaro clinical programme. NICE reviewed this evidence and recommended tirzepatide in its technology appraisal TA1026, published in December 2024.

Orlistat's trial data is older and the effect sizes are smaller. In systematic reviews, orlistat at 120mg typically produces 3–5 kg more weight loss than placebo over one year, translating to roughly 5–10% of starting weight in participants who adhere to a low-fat diet. The NHS medicines page for orlistat summarises the expected results and side effects clearly. The gap between the two medicines in absolute weight loss terms is substantial.

It is worth being honest: some people find orlistat a perfectly adequate tool, especially at lower starting BMI or when paired with strong dietary support. The numbers alone do not tell you what is right for your body.

Step 3, weigh up eligibility and practical fit

You may be reading this because you already take orlistat and are wondering whether Mounjaro is a step up, or because you want to know which to start with. Either way, eligibility shapes the answer before preference does.

Orlistat at 60mg is available from a pharmacist; the prescription-strength 120mg requires a GP or prescriber. Mounjaro is Prescription-Only at every dose, requires formal clinical assessment, and is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension, type 2 diabetes or high cholesterol. BMI alone does not determine approval, a prescriber reviews the full clinical picture before any prescription is issued.

There are also questions about using both at the same time. Some people ask whether orlistat and Mounjaro could be combined, and that is a conversation for a prescriber rather than something to decide independently, the clinical considerations around taking both together are worth reading if that is where your thinking is heading. Separately, if you are curious whether there is a scenario where orlistat adds something to a Mounjaro regimen, the orlistat and Mounjaro combination page covers the practical and safety detail.

Cost is also a real factor. Mounjaro's UK private price has risen significantly since Eli Lilly adjusted its list price in September 2025, that context is set out on the Mounjaro price increase page for anyone weighing up options. Orlistat is considerably cheaper. If budget is the primary constraint, a prescriber can help you understand what is clinically appropriate within it, which is a better starting point than choosing the cheaper option in isolation.

Step 4, how a prescriber actually makes this call

A clinician comparing orlistat and Mounjaro for a specific patient looks at BMI, comorbidities, previous weight-loss attempts, GI history (orlistat's side effects can be contraindicated in some bowel conditions), any current medicines, and what the person can realistically sustain. They are not running through a checklist in the order you might expect. Someone with a BMI of 28 and early hypertension might be a good candidate for Mounjaro and not eligible for prescription orlistat on current guidelines. Someone with a BMI of 32 and no comorbidities might be offered orlistat while Mounjaro eligibility is considered. Our clinical team reviews each consultation individually, a prescriber reads your answers the same day, not software.

If you want to understand the broader evidence base for Mounjaro before deciding whether to start a consultation, the clinical evidence review covers the trial data and NICE position in detail. And if the difference in licensing between orlistat and Mounjaro is still unclear, the orlistat vs Mounjaro licensing page unpacks that specifically.

Choosing between these two medicines is genuinely not straightforward, and feeling uncertain about it is completely reasonable. The right answer depends on factors only a prescriber can assess properly. If you want that assessment without a GP wait, a free consultation with our prescribers at nume is the next step.